eric
03-18-2004, 09:30 AM
Compounds Found To Induce Cell Death
By M.S.W. ZoeMed Inc. Copyright © 2004 All rights Reserved
--------------------------------------------------------------------------------
Maxim Pharmaceuticals has entered into an agreement with Shire BioChem Inc. under which Maxim has reacquired the rights to the MX2105 series of vascular targeting agent cancer drug candidates. The series was licensed in July 2000 to BioChemPharma a company that was subsequently acquired by ShirePharmaceuticals. In July 2003 Shire Pharmaceuticals announced that it was exiting the field of oncology research creating the opportunity for Maxim to reacquire the rights to the MX2105 series of compounds.
One of the lead compounds MX116407 demonstrated statistically significant anti-tumor activity and produced tumor regression as a single agent in animal lung cancer models. In addition the combination of MX116407 and certain cytotoxic agents demonstrated statistically significant anti-tumor activity and tumor regression and a higher rate of complete cures than the combination of other reported vascular targeting agents combined with cytotoxics. MX116407 is being prepared for studies designed to support the initiation of human clinical trials.
Compounds within the MX2105 series have been tested in multiple tumor xenograft models and have demonstrated activity against multiple cancer types including breast cancer lung cancer and colorectal cancer. The new agreement calls for Maxim to pay Shire BioChem certain milestone and royalty payments upon the successful advancement of any drug candidates within the MX2105 series.
"We were pleased to have the opportunity to consolidate the rights to MX2105 series within Maxim as this compound family complements our existing portfolio of apoptosis cancer drug candidates " said Larry G. Stambaugh Maxim's Chairman and Chief Executive Officer. "Our research team has been successful at identifying a diverse group of compounds that induce apoptosis in cancer cells through novel mechanisms of which the MX2105 series is one example."
Cancer LifeCenter Article 9330
By M.S.W. ZoeMed Inc. Copyright © 2004 All rights Reserved
--------------------------------------------------------------------------------
Maxim Pharmaceuticals has entered into an agreement with Shire BioChem Inc. under which Maxim has reacquired the rights to the MX2105 series of vascular targeting agent cancer drug candidates. The series was licensed in July 2000 to BioChemPharma a company that was subsequently acquired by ShirePharmaceuticals. In July 2003 Shire Pharmaceuticals announced that it was exiting the field of oncology research creating the opportunity for Maxim to reacquire the rights to the MX2105 series of compounds.
One of the lead compounds MX116407 demonstrated statistically significant anti-tumor activity and produced tumor regression as a single agent in animal lung cancer models. In addition the combination of MX116407 and certain cytotoxic agents demonstrated statistically significant anti-tumor activity and tumor regression and a higher rate of complete cures than the combination of other reported vascular targeting agents combined with cytotoxics. MX116407 is being prepared for studies designed to support the initiation of human clinical trials.
Compounds within the MX2105 series have been tested in multiple tumor xenograft models and have demonstrated activity against multiple cancer types including breast cancer lung cancer and colorectal cancer. The new agreement calls for Maxim to pay Shire BioChem certain milestone and royalty payments upon the successful advancement of any drug candidates within the MX2105 series.
"We were pleased to have the opportunity to consolidate the rights to MX2105 series within Maxim as this compound family complements our existing portfolio of apoptosis cancer drug candidates " said Larry G. Stambaugh Maxim's Chairman and Chief Executive Officer. "Our research team has been successful at identifying a diverse group of compounds that induce apoptosis in cancer cells through novel mechanisms of which the MX2105 series is one example."
Cancer LifeCenter Article 9330